NASDAQ:NEPH Nephros (NEPH) Stock Price, News & Analysis $1.46 +0.01 (+0.69%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Nephros Stock (NASDAQ:NEPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nephros alerts:Sign Up Key Stats Today's Range$1.46▼$1.4850-Day Range$1.36▼$1.8952-Week Range$1.36▼$4.04Volume893 shsAverage Volume15,190 shsMarket Capitalization$15.38 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewNephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Nephros Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks53rd Percentile Overall ScoreNEPH MarketRank™: Nephros scored higher than 53% of companies evaluated by MarketBeat, and ranked 568th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNephros has received no research coverage in the past 90 days.Read more about Nephros' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nephros is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nephros is -11.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNephros has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nephros' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently decreased by 76.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNephros does not currently pay a dividend.Dividend GrowthNephros does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently decreased by 76.92%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentNephros has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nephros this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nephros insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Nephros is held by insiders.Percentage Held by Institutions41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nephros' insider trading history. Receive NEPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. Email Address NEPH Stock News HeadlinesNephros Schedules Third Quarter 2024 Financial Results Conference CallOctober 31 at 7:30 AM | globenewswire.comNephros launches HydraGuard 20″ UltraFilterOctober 25, 2024 | finance.yahoo.comWhy Buffett, Bezos, & Congress Are Piling Into This One SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…November 2, 2024 | InvestorPlace (Ad)Nephros Delivers Critical Disaster Response to Support Hospitals and Care Facilities Impacted by Hurricanes Helene and MiltonOctober 17, 2024 | globenewswire.comNephros Inc (NEPH) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges with ...October 9, 2024 | finance.yahoo.comMMTC Micro Imaging Technology, Inc.September 25, 2024 | seekingalpha.comOne Forecaster Is Now More Bearish On Nephros, Inc. (NASDAQ:NEPH) Than They Used To BeAugust 14, 2024 | finance.yahoo.comUS$4.75 - That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After These ResultsAugust 12, 2024 | finance.yahoo.comSee More Headlines NEPH Stock Analysis - Frequently Asked Questions How have NEPH shares performed this year? Nephros' stock was trading at $3.46 at the beginning of the year. Since then, NEPH stock has decreased by 57.8% and is now trading at $1.4589. View the best growth stocks for 2024 here. How were Nephros' earnings last quarter? Nephros, Inc. (NASDAQ:NEPH) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.02. The firm earned $3.25 million during the quarter. Nephros had a negative trailing twelve-month return on equity of 15.64% and a negative net margin of 9.40%. How do I buy shares of Nephros? Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nephros own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/08/2024Today11/02/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NEPH CUSIPN/A CIK1196298 Webwww.nephros.com Phone(201) 343-5202Fax201-343-5207Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+242.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,580,000.00 Net Margins-9.40% Pretax Margin-9.40% Return on Equity-15.64% Return on Assets-11.43% Debt Debt-to-Equity RatioN/A Current Ratio4.06 Quick Ratio2.62 Sales & Book Value Annual Sales$14.24 million Price / Sales1.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book1.82Miscellaneous Outstanding Shares10,540,000Free Float10,112,000Market Cap$15.38 million OptionableNot Optionable Beta1.18 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:NEPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.